Browse > Article

B Cells Transduced with HPV16 E6/E7-expressing Adenoviral Vector Can Efficiently Induce CTL-dependent Anti-Tumor Immunity  

Kim, Yun-Sun (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Ko, Hyun-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Kim, Yeon-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Han, Seung-Hee (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Lee, Jung-Mi (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Chang, Woo-Sung (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Jin, Hyun-Tak (Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology)
Sung, Young-Chul (Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology)
Kang, Chang-Yuil (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Publication Information
IMMUNE NETWORK / v.7, no.3, 2007 , pp. 109-116 More about this Journal
Abstract
Background: Human papillomavirus (HPV) infection is responsible for cervical cancer, a common cancer in women. Since HPV infection and cancer development are controlled by the host immune system, immunotherapy against HPV can be helpful in preventing or treating HPV-associated cervical cancer. Two oncoproteins of HPV16, E6 and E7, are promising targets for immunotherapy against cervical cancer, because they are constitutively expressed in cervical cancer. Methods: Since cellular vaccines using B cells as well as dendritic cells offer an efficient approach to cancer immunotherapy, we opted to use B cells. We evaluated the immunogenicity and anti-tumor effects of a B cell vaccine transduced with HPV16 E6/E7-expressing adenovirus. Results: Vaccination with HPV16 E6/E7-transduced B cells induced E6/E7-specific $CD8^+$ T cell-dependent immune responses and generated anti-tumor effects against E6/E7-expressing TC-1 tumor. The anti-tumor effect induced by this B cell vaccine was similar to that elicited by DC vaccine, showing that B cells can be used as an alternative to dendritic cells for cellular vaccines. Conclusion: Thisstudy has shown the feasibility of using B cells as immunogenic APCs and the potential for developing prophylactic and therapeutic vaccines against HPV-associated cervical cancer using a B cell vaccine transduced with adenovirus expressing HPV16 E6/E7.
Keywords
HPV16 E6/E7; adenoviral vector; B cells; anti-tumor immunity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7;11-22, 2007   DOI   ScienceOn
2 Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2;59-65, 2002   DOI   ScienceOn
3 Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6;753-763, 2006   DOI   ScienceOn
4 Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC: Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171;2970-2976, 2003   DOI   PUBMED
5 Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH: A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 13;481-488, 2006   DOI
6 Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70;960-965, 1996   PUBMED
7 Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5;296-306, 2005   DOI   ScienceOn
8 Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF: Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol 139;458-467, 2005   DOI   ScienceOn
9 Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175;131-138, 1992   DOI   ScienceOn
10 Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, Kang CY: CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 66;6843-6850, 2006   DOI   ScienceOn
11 Rodriguez-Pinto D: B cells as antigen presenting cells. Cell Immunol 238;67-75, 2005   DOI   ScienceOn
12 Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D: Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11;4717-4723, 2005   DOI   ScienceOn
13 Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P: A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175;7297-7302, 2005   DOI   PUBMED
14 Lyakh LA, Koski GK, Young HA, Spence SE, Cohen PA, Rice NR: Adenovirus type 5 vectors induce dendritic cell differentiation in human CD 14(+) monocytes cultured under serum-free conditions. Blood 99;600-608, 2002   DOI   ScienceOn
15 Gallo P, Dharmapuri S, Cipriani B, Monaci P: Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther; 12 Suppl 1;S84-91, 2005   DOI   ScienceOn
16 Jin HT, Youn JI, Kim HJ, Lee JB, Ha SJ, Koh JS, Sung YC: Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 16;328-338, 2005   DOI   ScienceOn
17 Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76;287-299, 1994   DOI   ScienceOn
18 Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC: Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-rumor immunity. Gene Ther 7;726-733, 2000   PUBMED
19 Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, Glaubitz M, Niesert S, Kuhnle H, Schedel I: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57;836-840, 1994   DOI   ScienceOn
20 Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG: Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113;472-481, 2004   DOI   ScienceOn
21 Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR: B cells directly tolerize CD8(+) T cells. J Exp Med 188;1977-1983, 1998   DOI
22 Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A: Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol 68;75-85, 2007   DOI   ScienceOn
23 zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2;342-350, 2002   DOI   ScienceOn
24 Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F: Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. J Immunol 176;4012-4020, 2006   DOI   PUBMED
25 Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M, Pfister H, Fritsch P: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356;1985-1986, 2000   DOI   ScienceOn
26 Xia D, Moyana T, Xiang J: Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 16;241-259, 2006   DOI   ScienceOn
27 Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3; 133-146, 2003   DOI   ScienceOn
28 Schultze JL, Grabbe S, von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol;25:659-664, 2004   DOI   ScienceOn
29 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392;245-252, 1998   DOI   ScienceOn
30 Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto M, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169;2164-2171, 2002   DOI   PUBMED